GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Other Current Payables

Biomarin Pharmaceutical (MIL:1BMRN) Other Current Payables : €103 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Other Current Payables?

Biomarin Pharmaceutical's Other Current Payables for the quarter that ended in Mar. 2024 was €103 Mil.

Biomarin Pharmaceutical's quarterly Other Current Payables declined from Sep. 2023 (€108 Mil) to Dec. 2023 (€101 Mil) but then increased from Dec. 2023 (€101 Mil) to Mar. 2024 (€103 Mil).

Biomarin Pharmaceutical's annual Other Current Payables increased from Dec. 2021 (€56 Mil) to Dec. 2022 (€81 Mil) and increased from Dec. 2022 (€81 Mil) to Dec. 2023 (€101 Mil).


Biomarin Pharmaceutical Other Current Payables Historical Data

The historical data trend for Biomarin Pharmaceutical's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Other Current Payables Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.16 67.96 55.93 81.15 101.31

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.79 94.17 108.38 101.31 102.84

Biomarin Pharmaceutical Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Biomarin Pharmaceutical Other Current Payables Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines